Back to results
US 7,452,896 B2Granted
Pyrimidine-sulfamides and their use as endothelian receptor antagonist
AssigneeActelion Pharmaceuticals Ltd.
InventorsMartin Bolli, Christoph Boss, Martine Clozel, Walter Fischli, Thomas Weller
Life of this patent
Estimating the term…
Abstract
The invention relates to novel sulfamic acid amides of General Formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.
Claims13
A compound of the general formula I,
- wherein
- R1 represents lower alkyl-O—(CH2)n—, cycloalkyl-O—(CH2)n—, cycloalkyl-CH2—O—(CH2)n—;
- R2 represents —CH3;
- Ra—Y—(CH2)m—;
- R3 represents aryl;
- heteroaryl;
- R4 represents hydrogen;
- trifluoromethyl;
- lower alkyl;
- lower alkyl-amino;
- lower alkyloxy;
- lower alkyloxy-lower alkyloxy;
- hydroxy-lower alkyloxy;
- lower alkyl-sulfinyl;
- lower alkylthio;
- lower alkylthio-lower alkyl;
- hydroxy-lower alkyl;
- lower alkyloxy-lower alkyl;
- hydroxy-lower alkyloxy-lower alkyl;
- hydroxy-lower alkyl-amino;
- lower alkylamino-lower alkyl;
- amino;
- di-lower alkylamino;
- [N-(hydroxy-lower alkyl)-N-(lower alkyl)]-amino;
- aryl;
- arylamino;
- aryl-lower alkylamino;
- aryl-thio;
- aryl-lower alkylthio;
- aryloxy;
- aryl-lower alkyloxy;
- aryl-lower alkyl;
- arylsulfinyl;
- heteroaryl;
- heteroaryl-oxy;
- heteroarylamino;
- heteroarylthio;
- heteroaryl-lower alkyl;
- heteroarylsulfinyl;
- heterocyclyl;
- heterocyclyl-lower alkyloxy;
- heterocyclyloxy;
- heterocyclylamino;
- heterocyclyl-lower alkylamino;
- heterocyclylthio;
- heterocyclyl-lower alkylthio;
- heterocyclyl-lower alkyl;
- heterocyclylsulfinyl;
- cycloalkyl;
- cycloalkyloxy;
- cycloalkyl-lower alkyloxy;
- cycloalkylamino;
- cycloalkyl-lower alkylamino;
- cycloalkylthio;
- cycloalkyl-lower alkylthio;
- cycloalkyl-lower alkyl;
- cycloalkylsulfinyl;
- R6 represents hydrogen or methyl;
- X represents oxygen;
- sulfur;
- —CH2— or a bond;
- Y represents a bond, —O—;
- —NH—;
- —SO2—NH—;
- —NH—SO2—NH—;
- —O—CO—;
- —CO—O—;
- —O—CO—NH—;
- —NH—CO—O—;
- —NH—CO—NH—;
- n represents the integers 2, 3, or 4;
- m represents the integers 2, 3, or 4;
- and
- Ra represents aryl, heteroaryl, lower alkyl, cycloalkyl, hydrogen;
- and optically pure enantiomers, mixtures of enantiomers, optically pure diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.
72 more elements
A compound selected from the group consisting of:
- 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide;
- 2-Methoxy-ethanesulfamic acid {5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-amide;
- 2-Methoxy-ethanesulfamic acid {5-(4-bromophenyl)-6-[2-(5-methylsulfanyl-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-amide;
- and
- 2-Methoxy-ethanesulfamic acid {5-(4-bromophenyl)-6-[2-(5-methoxypyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-amide.
2 more elements
Dependencies are inferred from the claim text.